SK Biopharmaceuticals Co., Ltd. (KRX: 326030)

SK Biopharmaceuticals Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	284,862	239,700	104,060	225,922	59,333	51,141
Short-Term Investments	1,589	1,418	201,394	108,417	328,657	31,234
Cash & Short-Term Investments	286,452	241,118	305,454	334,339	387,991	82,374
Cash Growth	28.52%	-21.06%	-8.64%	-13.83%	371.01%	7.64%
Accounts Receivable	136,809	111,001	63,506	55,883	8,563	189.43
Other Receivables	730.86	2,641	2,945	1,477	3,990	1,949
Receivables	137,540	113,642	66,451	57,360	12,553	2,138
Inventory	127,115	102,525	90,920	51,933	23,040	6,733
Prepaid Expenses	34,759	25,898	18,734	20,964	10,920	5,225
Other Current Assets	4,045	5,538	6,366	6,622	99.95	2,210
Total Current Assets	589,910	488,722	487,925	471,219	434,603	98,681
Property, Plant & Equipment	45,246	47,753	20,350	22,938	24,233	25,897
Long-Term Investments	101,545	104,091	99,959	107,665	6,849	7
Goodwill	3,654	3,392	-	-	-	-
Other Intangible Assets	11,213	14,542	17,181	18,900	19,695	883.32
Long-Term Deferred Tax Assets	53,167	44,723	29,641	18,919	11,837	13,550
Long-Term Deferred Charges	9,794	9,090	-	-	-	-
Other Long-Term Assets	9,445	10,771	9,107	3,985	3,025	13.69
Total Assets	824,080	723,171	664,241	643,652	500,241	139,073
Accounts Payable	17,382	2,346	23,106	16,931	8,954	-
Accrued Expenses	54,870	71,331	55,035	64,776	36,543	35,103
Short-Term Debt	50,000	50,000	-	-	-	100,000
Current Portion of Leases	6,626	7,061	5,644	5,481	4,906	3,197
Current Income Taxes Payable	32.9	88.78	208.36	1,997	-	-
Other Current Liabilities	132,707	110,792	79,079	59,120	20,193	7,341
Total Current Liabilities	359,546	241,619	163,073	148,306	70,595	145,641
Long-Term Debt	25,000	94,484	143,722	-	-	-
Long-Term Leases	26,682	26,505	6,530	10,256	13,572	5,858
Long-Term Deferred Tax Liabilities	2,057	1,909	-	-	-	-
Other Long-Term Liabilities	39,279	37,703	34,356	40,850	36,915	-
Total Liabilities	452,563	402,219	347,681	199,465	121,175	152,098
Common Stock	39,157	39,157	39,157	39,157	39,157	32,500
Additional Paid-In Capital	1,084,848	1,084,848	1,084,848	1,084,848	1,084,848	446,040
Retained Earnings	-820,707	-861,561	-827,555	-689,141	-746,951	-498,948
Comprehensive Income & Other	34,928	21,243	20,112	9,325	2,013	7,383
Total Common Equity	338,226	283,686	316,560	444,187	379,067	-13,025
Minority Interest	33,291	37,265	-	-	-	-
Shareholders' Equity	371,517	320,951	316,560	444,187	379,067	-13,025
Total Liabilities & Equity	824,080	723,171	664,241	643,652	500,241	139,073
Total Debt	206,235	178,050	155,896	15,738	18,478	109,055
Net Cash (Debt)	80,217	63,068	149,558	318,602	369,513	-26,681
Net Cash Growth	19.28%	-57.83%	-53.06%	-13.78%	-	-
Net Cash Per Share	1024.31	805.33	1909.74	4068.30	5148.87	-410.47
Filing Date Shares Outstanding	78.31	78.31	78.31	78.31	78.31	65
Total Common Shares Outstanding	78.31	78.31	78.31	78.31	78.31	65
Working Capital	230,364	247,104	324,852	322,914	364,007	-46,960
Book Value Per Share	4318.88	3622.46	4042.23	5671.93	4840.39	-200.39
Tangible Book Value	323,358	265,752	299,380	425,288	359,371	-13,909
Tangible Book Value Per Share	4129.04	3393.45	3822.85	5430.60	4588.90	-213.98
Buildings	-	-	-	-	159.12	121.75
Machinery	31,716	30,611	21,078	19,165	18,238	16,066
Construction In Progress	169.23	236.84	1,643	1,276	375.64	10,616

Source: S&P Capital IQ. Standard template. Financial Sources.